A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.
https://european-biotechnology.com/wp-content/uploads/2024/04/tk322_Zigarette_tg.jpg12711920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-08-22 12:39:002024-04-04 16:46:05Cancer: Western life style is a killer
https://european-biotechnology.com/wp-content/uploads/2024/04/Biovector_Pharma.jpg7201280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-08-16 07:18:002024-04-04 16:46:08Vector Biopharma kicks of with CHF30m Series A financing
https://european-biotechnology.com/wp-content/uploads/2024/04/B-Medical-Systems-Factory-Lux-Wort-10.jpeg16152422Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-08-09 15:46:272024-04-04 16:46:10Azenta set to acquire B Medical Systems
Sartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
https://european-biotechnology.com/wp-content/uploads/2024/04/Albumedix.jpg400800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-08-09 07:45:092024-04-04 16:46:11Sartorius pays £415m for Albumedix Ltd
As Genmabs Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.
Belgian eTheRNA raises €39m in Series B2 financing
Latest NewsModerna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA.
Kinarus announces CHF 20 million convertible bond issue
Latest NewsKinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.
Cancer: Western life style is a killer
Latest NewsA study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.
Ryvu Therapeutics bags €22m from EIB
Latest NewsPolish cancer drug developer, Ryvu Therapeutics, has received €22m funding from the European Investment Bank via its venture debt instrument.
Largest beer brewer to use sustainable PEF bottles
Latest NewsAvantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
Vector Biopharma kicks of with CHF30m Series A financing
Latest NewsWith a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.
Two deaths with Novartis gene therapy
Latest NewsSwiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.
Azenta set to acquire B Medical Systems
Latest NewsAzenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for €410m.
Sartorius pays £415m for Albumedix Ltd
Latest NewsSartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
BioNtech SE expands collab with Genmab A/S
Latest NewsAs Genmabs Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.